Your session is about to expire
← Back to Search
Local Anaesthetic
Local Anaesthetic Injection for Postoperative Pain in Inguinal Hernia
Phase 3
Recruiting
Research Sponsored by Cali Pharmaceuticals LLC
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
others
Scheduled to have inguinal hernia repair
Must not have
Previously inguinal herniorrhaphy
Impaired renal function (e.g., creatinine > 1.5 × ULN)
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 72 hours
Awards & highlights
Pivotal Trial
Summary
This trial tests a new treatment called CPL-01 on patients who had hernia surgery to see which helps recovery best.
Who is the study for?
This trial is for healthy adults aged 18-75 with a BMI ≤ 39 kg/m2, scheduled for inguinal hernia repair. Participants must be able to consent and complete study procedures. Women can't be pregnant or planning pregnancy; men must use birth control. Exclusions include prior herniorrhaphy, significant health issues, concurrent painful conditions requiring analgesics, certain heart problems within the last year, specific genetic disorders, liver or kidney impairment, recent malignancy or opioid use.
What is being tested?
The trial tests the effectiveness of CPL-01 against postoperative pain following herniorrhaphy compared to a positive control (known effective treatment) and negative control (placebo or standard care). Subjects are randomly assigned to one of these groups after surgery and monitored thereafter.
What are the potential side effects?
Potential side effects from local anaesthetic injections like CPL-01 may include temporary numbness around the injection site, bruising or bleeding at the injection spot, allergic reactions ranging from mild irritation to more severe responses depending on individual sensitivity.
Eligibility Criteria
Inclusion Criteria
You may be eligible if you check “Yes” for the criteria belowSelect...
This criterion does not apply to me.
Select...
I am scheduled for inguinal hernia surgery.
Select...
I am using birth control methods approved by my doctor.
Select...
I am not pregnant nor planning to become pregnant.
Exclusion Criteria
You may be eligible for the trial if you check “No” for criteria below:Select...
I have had surgery for a groin hernia before.
Select...
My kidney function is not normal.
Select...
I have been diagnosed with cancer within the last year.
Select...
My liver isn't working well (e.g., high ALT or bilirubin levels).
Select...
I have a history of malignant hyperthermia or G6PD deficiency.
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 72 hours
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~72 hours
Treatment Details
Study Objectives
Study objectives can provide a clearer picture of what you can expect from a treatment.Primary study objectives
Pain control
Awards & Highlights
Pivotal Trial
The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Trial Design
3Treatment groups
Experimental Treatment
Active Control
Placebo Group
Group I: CPL-01Experimental Treatment1 Intervention
Local infiltration of CPL-01
Group II: Ropivacaine HClActive Control1 Intervention
Local infiltration of Naropin
Group III: PlaceboPlacebo Group1 Intervention
Local infiltration of Saline Placebo
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
local anaesthetic injection
2018
Completed Phase 4
~610
Research Highlights
Information in this section is not a recommendation. We encourage patients to speak with their healthcare team when evaluating any treatment decision.Mechanism Of Action
Side Effect Profile
Prior Approvals
Other Research
The most common treatments for inguinal hernia primarily involve surgical repair, such as open herniorrhaphy or laparoscopic surgery, which work by repositioning the herniated tissue and reinforcing the abdominal wall, often with mesh implants. This is crucial for preventing complications like tissue strangulation.
Postoperative pain management, which may include analgesics, anti-inflammatory medications, or local anesthetics, helps reduce pain and inflammation, facilitating quicker recovery and improving patient comfort. Understanding these mechanisms is important for patients to appreciate how these treatments address both the structural and symptomatic aspects of inguinal hernia.
Find a Location
Who is running the clinical trial?
Cali Pharmaceuticals LLCLead Sponsor
4 Previous Clinical Trials
772 Total Patients Enrolled
Erol OnelStudy DirectorCali Biosciences
2 Previous Clinical Trials
647 Total Patients Enrolled
Media Library
Eligibility Criteria:
This trial includes the following eligibility criteria:- This criterion does not apply to me.I have had surgery for a groin hernia before.I have a painful condition that might need painkillers.My kidney function is not normal.I have been diagnosed with cancer within the last year.My liver isn't working well (e.g., high ALT or bilirubin levels).Your body mass index is less than 39.I haven't had a heart attack, heart surgery, or serious heart rhythm problems in the last year.I have a history of malignant hyperthermia or G6PD deficiency.I don't have any health issues that would stop me from joining the study.I am between 18 and 75 years old and in good health.I am scheduled for inguinal hernia surgery.I am using birth control methods approved by my doctor.I am willing and able to follow the study's procedures.I have used opioids daily for a week or more in the last 6 months.I am not pregnant nor planning to become pregnant.
Research Study Groups:
This trial has the following groups:- Group 1: CPL-01
- Group 2: Placebo
- Group 3: Ropivacaine HCl
Awards:
This trial has 1 awards, including:- Pivotal Trial - The final step before approval, pivotal trials feature drugs that have already shown basic safety & efficacy.
Timeline:
This trial has the following timeline:- Screening: It may take up to 3 Weeks to process to see if you qualify in this trial.
- Treatment: The duration you will receive the treatment varies.
- Follow Ups: You may be asked to continue sharing information regarding the trial for 6 Months after you stop receiving the treatment.
Inguinal Hernia Patient Testimony for trial: Trial Name: NCT05813847 — Phase 3
Share this study with friends
Copy Link
Messenger